📰 Triple Therapy News
Triple Therapy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Triple Therapy. Real-time updates on events, politics, business and more.
April 26, 2024
Media Update New data presented at ATS demonstrate Sanofis leadership in advancing potential new therapies for patients with immune-mediated respiratory...
February 20, 2024
Patients with chronic obstructive pulmonary disease (COPD) on triple therapy face an increased cardiovascular risk.
February 9, 2024
This retrospective cohort study evaluated baseline demographics, clinical characteristics, and treatment patterns of US patients with asthma who newly initiated single- or multiple-inhaler triple therapy.
October 11, 2023
Two posters presented at the CHEST Annual Meeting 2023 showed how real-world exacerbation rates in asthma and chronic obstructive pulmonary disease (COPD) dropped after patients started using a single inhaler that delivers triple therapy.
September 8, 2023
On August 4, 2023, the Food and Drug Administration (“FDA”) Office of Prescription Drug Promotion (“OPDP”) issued a Warning Letter to AstraZeneca which stated that the company made...
May 25, 2023
Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.
April 26, 2023
Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.
April 26, 2023
A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.
March 1, 2023
The chronic obstructive pulmonary disease (COPD) research community has made substantial progress in the past 10 years. The most important paradigm shifts have been achieved in the prevention, biological assessment, and precision treatment of COPD exacerbations. Exacerbations account for most of the morbidity and mortality in patients with COPD.1 Instead of accepting these events as inevitable, COPD clinicians now have effective treatments to prevent them. The Informing the Pathway of COPD Treat...
October 24, 2022
/CNW/ - Today, AstraZeneca announced the Canadian availability of Breztri™ Aerosphere® (budesonide/glycopyrronium/formoterol fumarate dihydrate), indicated for...